Antagonizing Retinoic Acid Receptors Increases Myeloid Cell Production by Cultured Human Hematopoietic Stem Cells
Overview
Affiliations
Activities of the retinoic acid receptor (RAR)α and RARγ are important to hematopoiesis. Here, we have investigated the effects of receptor selective agonists and antagonists on the primitive human hematopoietic cell lines KG1 and NB-4 and purified normal human hematopoietic stem cells (HSCs). Agonizing RARα (by AGN195183) was effective in driving neutrophil differentiation of NB-4 cells and this agonist synergized with a low amount (10 nM) of 1α,25-dihydroxyvitamin D to drive monocyte differentiation of NB-4 and KG1 cells. Treatment of cultures of human HSCs (supplemented with stem cell factor ± interleukin 3) with an antagonist of all RARs (AGN194310) or of RARα (AGN196996) prolonged the lifespan of cultures, up to 55 days, and increased the production of neutrophils and monocytes. Slowing down of cell differentiation was not observed, and instead, hematopoietic stem and progenitor cells had expanded in number. Antagonism of RARγ (by AGN205728) did not affect cultures of HSCs. Studies of CV-1 and LNCaP cells transfected with RAR expression vectors and a reporter vector revealed that RARγ and RARβ are activated by sub-nM all-trans retinoic acid (EC-0.3 nM): ~50-fold more is required for activation of RARα (EC-16 nM). These findings further support the notion that the balance of expression and activity of RARα and RARγ are important to hematopoietic stem and progenitor cell expansion and differentiation.
Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer.
Hantusch B, Kenner L, Stanulovic V, Hoogenkamp M, Brown G Int J Mol Sci. 2024; 25(17).
PMID: 39273194 PMC: 11394715. DOI: 10.3390/ijms25179245.
Molecular Interactions of Selective Agonists and Antagonists with the Retinoic Acid Receptor γ.
Powala K, Zolek T, Brown G, Kutner A Int J Mol Sci. 2024; 25(12).
PMID: 38928275 PMC: 11203493. DOI: 10.3390/ijms25126568.
Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A Pharmacol Rev. 2023; 75(6):1233-1318.
PMID: 37586884 PMC: 10595025. DOI: 10.1124/pharmrev.121.000436.
Deregulation of All- Retinoic Acid Signaling and Development in Cancer.
Brown G Int J Mol Sci. 2023; 24(15).
PMID: 37569466 PMC: 10419198. DOI: 10.3390/ijms241512089.
The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away.
Nagai Y, Ambinder A Cancers (Basel). 2023; 15(14).
PMID: 37509198 PMC: 10377082. DOI: 10.3390/cancers15143535.